Mirabella Financial Services LLP Sells 26,875 Shares of Stryker Co. (NYSE:SYK)

Mirabella Financial Services LLP reduced its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 82.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,825 shares of the medical technology company's stock after selling 26,875 shares during the quarter. Mirabella Financial Services LLP's holdings in Stryker were worth $2,096,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of SYK. MML Investors Services LLC boosted its stake in shares of Stryker by 8.8% during the 4th quarter. MML Investors Services LLC now owns 38,491 shares of the medical technology company's stock worth $13,859,000 after acquiring an additional 3,099 shares during the period. MetLife Investment Management LLC boosted its position in Stryker by 1.6% during the fourth quarter. MetLife Investment Management LLC now owns 95,883 shares of the medical technology company's stock worth $34,523,000 after purchasing an additional 1,500 shares during the period. Norinchukin Bank The increased its holdings in shares of Stryker by 8.8% in the fourth quarter. Norinchukin Bank The now owns 15,260 shares of the medical technology company's stock valued at $5,494,000 after purchasing an additional 1,228 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Stryker by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 828,303 shares of the medical technology company's stock valued at $298,246,000 after purchasing an additional 18,897 shares during the period. Finally, Forum Financial Management LP lifted its stake in shares of Stryker by 31.7% during the 4th quarter. Forum Financial Management LP now owns 2,455 shares of the medical technology company's stock worth $884,000 after buying an additional 591 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on SYK shares. Needham & Company LLC reissued a "buy" rating and issued a $442.00 price target on shares of Stryker in a report on Friday, March 21st. The Goldman Sachs Group set a $422.00 price target on Stryker in a research note on Tuesday, March 4th. JPMorgan Chase & Co. upped their price target on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Wells Fargo & Company lifted their price objective on shares of Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Finally, Citigroup reiterated a "buy" rating and issued a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and an average price target of $423.53.

Stryker Price Performance

Shares of SYK traded up $3.83 during trading hours on Thursday, reaching $360.94. The stock had a trading volume of 1,349,722 shares, compared to its average volume of 1,357,113. The stock has a market capitalization of $137.77 billion, a PE ratio of 46.51, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The company's 50-day moving average is $368.69 and its two-hundred day moving average is $372.95.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the business earned $3.46 EPS. Research analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.93%. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.